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ABSTRACT
Objective: The aim of this study was to elicit the individual willingness to
pay (WTP) for a quality-adjusted life-year (QALY).
Methods: In a Web-based questionnaire containing contingent valuation
exercises, respondents valued health changes in ﬁve scenarios. In each
scenario, the respondents ﬁrst valued two health states on a visual analog
scale (VAS) and expressed their WTP for avoiding a decline in health from
the better health state to the worse, using a payment scale followed by a
bounded open contingent valuation question.
Analysis: WTP per QALY was calculated for QALY gains calculated using
VAS valuations, as well as the Dutch EQ-5D tariffs, the two steps in the
WTP estimations and each scenario. Heterogeneity in WTP per QALY
ratios was examined from the perspective of: 1) household income; and 2)
the level of certainty in WTP indicated by respondents. Theoretical validity
was analyzed using clustered multivariate regressions.
Results: A total of 1091 respondents, representative of the Dutch popu-
lation, participated in the survey. Mean WTP per QALY was €12,900
based on VAS valuations, and €24,500 based on the Dutch EuroQoL
tariffs. WTP per QALY was strongly associated with income, varying from
€5000 in the lowest to €75,400 in the highest income group. Respondents
indicating higher certainty exhibited marginally higher WTP. Regression
analyses conﬁrmed expected relations between WTP per QALY, income,
and other personal characteristics.
Conclusion: Individual WTP per QALY values elicited in this study are
similar to those found in comparable studies. The use of individual valu-
ations in social decision-making deserves attention, however.
Keywords: cost-effectiveness, individual preferences, QALY, resource allo-
cation, WTP.
Introduction
Decisions regarding reimbursement and allocation of funds
within the health-care budget increasingly are inﬂuenced by the
results of cost-effectiveness analysis (CEA). CEA evaluates two or
more alternative interventions in terms of their beneﬁts
(expressed in a nonmonetary measure) and costs, and summa-
rizes the result in an incremental cost-effectiveness ratio (ICER).
The ICER represents the additional costs per additional health
unit produced by one intervention in comparison to another. A
common measure of health in this context is the quality-adjusted
life-year (QALY), which comprises both length and quality of
life. When using the QALY as outcome measure, the ICER rep-
resents the ratio of incremental costs per QALY gained. Typically,
an intervention is considered cost-effective if the ICER falls
below a certain cost-effectiveness “threshold,” indicating some
monetary value of a QALY. Some 10 years ago, Johannesson and
Meltzer [1] argued that without explicating such a threshold
value, CEA cannot be considered a proper decision-making tool,
as it would lack a systematic and universally recognizable deci-
sion criterion.
Recent literature has seen a lively debate on implicit and
explicit cost-effectiveness threshold(s), although without reach-
ing consensus on the nature or height of an appropriate monetary
value of a QALY [2–7]. In the mean time, various institutions and
governmental bodies (such as the National Institute for Health
and Clinical Excellence [NICE] in the UK, Swedish Pricing and
Reimbursement board, Pharmaceutical Beneﬁts Advisory Com-
mittee in Australia, CVZ in The Netherlands) have adopted
threshold values in the process of optimizing the allocation of
health-care resources, albeit sometimes implicitly and inconsis-
tently. The acceptable ranges of the monetary value of a QALY
used in such decision-making, however, appear to be broad and
tend to lack empirical underpinning [8,9]. This underlines the
importance of further investigating the monetary value of a
QALY.
The apparent reluctance to research and estimate a “true”
value of a QALY has its roots in various arguments and in
empirical, theoretical, and methodological challenges inherent to
the process of obtaining such a number. For example, there is
evidence that the willingness to pay (WTP) for a QALY is non-
constant and dependent on the size, duration, and type of the
health gain [10–15]. It might thus be impossible to elicit a unique
individual WTP for a QALY, as suggested for example by Ble-
ichrodt and Quiggin [16]. Matters are additionally complicated
by the societal context of decision-making in health care. From
the societal perspective, which aligns with the decision-maker’s
approach, the beneﬁciaries from health-care services need not be
the payers of those services and therefore characteristics other
than the size of the health gain may play a role in the valuation
of QALYs. A review by Dolan et al. [17], for instance, showed
the age of the beneﬁciary to be an important equity consideration
that ought to be included in the social valuations of publicly
provided health-care services. The discrepancy between indi-
vidual and societal valuations, elicited from an ex ante or ex post
perspective, could be considerable [18].
In spite of these problems, it is important to continue research
in this area and work toward a higher level of transparency and
consistency in societal decision-making. Seeking to ﬁnd appro-
priate monetary values for QALY gains should not be seen as
necessarily attempting to establish a ﬁrm link between CBA and
CEA, but rather as an aid to decision-makers [12]. Indeed,
Weinstein [19] recently concluded that “it is time to lay to rest
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the mythical $50,000 per QALY standard and begin a real public
discourse on processes for deciding what health care services are
worth paying for.”
This study aimed at eliciting the ﬁrst empirical estimate of the
monetary value of a QALY in The Netherlands. In doing so, it
applies a carefully designed questionnaire, which draws on previ-
ous studies in this ﬁeld. Speciﬁcally, it uses a contingent valuation
approach, from the individual perspective and under certainty, to
answer how much are Dutch citizens willing to pay for a QALY
gain. This is one of three ways of determining what the optimal
cost-effectiveness threshold should be [2]. First, the threshold can
be inferred from previous decisions taken by leading institutions
such as NICE [3,8]. Second, it can be set to exhaust an exog-
enously determined budget [6]. Third, it can be set by identifying
the marginal value the society attaches to health. While WTP is a
common way of deriving the value of a commodity, only a few
studies have applied it in this area [15,20–22]. This study offers a
more comprehensive approach to WTP elicitation, in terms of the
number of health states valued (in absolute terms and per respon-
dent; e.g., 20, 21, 15), ensuring a good coverage of the QALY
scale. The two-step elicitation method WTP used in this study,
using a payment scale (PS) followed by a bounded direct follow-up
question, is also more comprehensive than was usually applied,
because it combines two (linked) elicitation questions in order to
arrive at a more precise estimate of the maximum WTP. This was
done to combine the ease of a PS with the precision of an
open-ended (OE) format. Moreover, throughout, the study applies
several different ways of mitigating the hypothetical nature of the
exercise. Finally, the robustness of the ﬁndings was ensured by
sample properties and size, arguably leading to larger generaliz-
ability of the results.
Conversely, like previous studies, the current study employs
the individual perspective to WTP elicitation. It is the ﬁrst step in
a larger research effort, designed to estimate the societal value of
a QALY in The Netherlands. As a part of a larger study, our
results offer a reference point for future ﬁndings and give impor-
tant practical insight on how to derive the appropriate values to
be used in social decision-making. We also aimed at comparing
our ﬁndings with the empirical estimates reported in the
literature.
In the following sections, we present the methodology and the
design of the study. We then present and discuss the main results
of the study and results of various subsample analysis. Finally,
our aim was to compare the value of a QALY to already existing
estimates, and discuss the underlying reasons for the differences
we might ﬁnd. Then, we discuss the practical implications of our
ﬁndings.
Methods
WTP for a QALY was elicited in a representative sample of the
general public in The Netherlands, by means of contingent valu-
ation. Former research showed that the general population (i.e.,
a heterogeneous, less health-literate sample) elicits more certain,
and less volatile health valuations and WTP estimates than
patient and/or decision-maker groups [23]. The respondents
were recruited by a professional Internet sampling company and
the questionnaire administered in October 2008 through the
Internet. Participants did not receive direct monetary compensa-
tion, but a small sum was donated to a charity of their choice,
upon completion of the questionnaire.
Survey Instrument
In the introduction to the questionnaire, the respondents were
briefed about the purpose and content of the questionnaire, and,
to help them understand the WTP exercises, were offered three
“warm-up” questions for nonhealth-related items (i.e., their
WTP for: 1) a car; 2) housing; and 3) a pair of shoes). Next, the
respondents were asked to describe their own health status using
the EQ-5D proﬁle and to rate own health, perfect health, and
death on the EQ-VAS [21]. The respondents had the possibility to
adapt the ratings until ﬁnal conﬁrmation was given.
After this introduction, the respondents solved ﬁve choice
scenarios. Each scenario contained two EQ-5D health proﬁles or
health states (please note, scenario design is discussed below).
The respondents were asked which of the two health states they
considered as the better one (see screen 1 in Appendix 1 found at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i8_Bobinac.asp) and then requested to place the two
health states on a visual analog scale (VAS) showing their previ-
ous valuations of current health, death, and perfect health (see
screen 2 in Appendix 1). Next, the respondents were asked to
imagine being in the health state they had chosen as the better
one and to indicate their WTP to avoid spending 1 year in the
health state they had chosen as the worse. This health loss (i.e.,
the difference between the better and the worse health state in the
scenario) could be avoided by taking a painless medicine of
unspeciﬁed properties once a month, for which one had to pay
out-of-pocket in 12 monthly instalments (see Appendix 1 at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i8_Bobinac.asp for the full question). The vehicle of health
improvement was only described as “painless medicine” in order
to remove any possible contamination of the health gain evalu-
ation according to the means by which that improvement would
be brought about [24].
Next, the WTP was elicited in a two-step procedure: ﬁrst, a
PS [25–29] was offered, followed by a bounded “OE” question.
The boundaries in the “OE” question were determined by the
amounts the respondents had indicated to certainly pay or cer-
tainly not pay in the PS phase.
In particular, in the ﬁrst step, the respondents were presented
with an ordered low-to-high PS of monthly installments (in €: 0,
10, 15, 25, 50, 75, 100, 125, 150, 250, 300, 500, 750, 1000,
1500, 2500), and asked to indicate the maximum amount they
would certainly pay (screen 3) and the ﬁrst amount they would
certainly not pay (screen 4 [27]). By asking the respondents to
identify all the amounts they would certainly pay and those that
they would certainly not pay, the method provided information
about the range of values over which people are uncertain [30].
In the second step, the respondents were presented with a
bounded direct “OE” follow-up question and asked to indicate
the maximum amount they would pay if asked to do so right
now. This maximum WTP was deemed as the appropriate esti-
mate to be used in the calculation of the WTP for a QALY, and
is our central WTP estimate. This estimate was bounded by the
higher and the lower value the respondents previously chose on
the PS (screen 5). The combination of two WTP questions,
although in the context of a bidding game, was applied before
(e.g., [31,32]). The two-step contingent valuation approach was
applied to arrive at a directly and precisely indicated estimate of
the maximum WTP within a range of WTP which was informed
by the results from the less precise, but informative and easy-to-
use PS. This two-step approach also added information and
potentially robustness to our ﬁndings because the respondents
used two different valuation techniques within one question-
naire. The beneﬁt of employing two different WTP formats,
although in a context of two entirely separate WTP questions,
was investigated by Johnson et al. [33].
Attention was also given to reducing the hypothetical bias
inherent in contingent valuation exercises, through ex ante and
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ex post mitigation [34]. Ex ante, the respondents were reminded
to take their household income into consideration when solving
the exercise [35]. Moreover, the visual image of health states
rated on the VAS remained present on the right-hand side of the
screen, as a reminder of the size of the health gain being valued
(see Appendix 1 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Bobinac.asp). Ex post, the respon-
dents were asked on which element of household spending they
would economize in order to be able to pay for the painless
medicine (answer options were: 1) food; 2) clothing; 3) entertain-
ment; 4) sport; 5) savings; 6) charity; and 7) other) [36]. To avoid
respondent fatigue and repetition, this was asked only at the end
of the ﬁrst of the ﬁve scenarios. Finally, the respondents were
asked to indicate the level of certainty in the answer provided.
They were asked to imagine having to pay the stated amount in
reality, and immediately, and the options included: 1) totally sure
I would pay the stated amount; 2) pretty sure I would pay the
stated amount; 3) neither sure nor unsure I would pay the stated
amount; 4) not very sure I would pay the stated amount; or 5)
unsure I would pay the stated amount. This follow-up question
was introduced to identify a subset of responses whose valua-
tions may more closely reﬂect their “true” WTP [36–38]. Nev-
ertheless, being surer in the valuation does not necessarily imply
that the elicited value is “true” or that it necessarily reﬂects the
revealed preference. It is only assumed that the stated WTP will
probably deviate more from “true” WTP when the respondents
are less sure about their answers.
When the respondents chose €0 as their maximum WTP, they
were asked to indicate the reason behind this preference (answer
options were: 1) I am unable to pay more than €0; 2) avoiding the
worse health state and remaining in the better health state in not
worth more than €0 to me; 3) I am not willing to pay out of
ethical considerations; 4) something else [with open text ﬁeld for
explanation]; options 1) and 2) were considered as true WTP,
options 3) and 4) as a protest answer).
The scenarios were presented in a random order to the
respondents as to control for possible order bias, although such
effects may not be entirely possible to eradicate [39]. Still, by
adopting a randomized order, the potential bias was distributed
more or less evenly across the blocks.
Following the main part of the questionnaire, the respon-
dents were asked about their socioeconomic and demographic
characteristics.
The questionnaire was pilot tested in a random sample of 100
respondents in order to determine the plausibility and clarity of
the tasks, the feasibility of the questionnaire as a whole, and to
test the range of the PS. The respondents had several opportuni-
ties to express their opinion about the tasks at hand. The results
of the pilot showed that the questionnaire was clear and feasible,
with no evidence to support the claim that the task was found
unrealistic. Moreover, the two-step contingent valuation exercise
proved feasible. The results of the pilot did point out that the
distribution and spread of the PS were not optimal; the initial
scale encompassed three value categories above €2500 (i.e.,
€5000, €7500, and €10,000), which were never chosen. To avoid
loss of information and possible anchoring to exaggerated high
values, the maximum was set at €2500 for the main study and
additional value categories were added to the scale around the
most frequently chosen values.
Design of Scenarios
Forty-two health states were paired into 29 choice scenarios
(see Appendix 2 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Bobinac.asp) representing a fair
spread of QALY gains across the utility plane (see Fig. 1). The
majority of the pairs was originally applied for deriving the UK
tariffs for the EQ-5D [40], and 16 out of the 29 pairs were also
applied in deriving the Dutch tariffs [41]. The few scenarios that
were not applied in deriving the UK or the Dutch tariffs were
chosen for the purpose of testing other hypotheses, on which the
current study does not focus. The 29 scenarios were split into 10
blocks of ﬁve scenarios, and randomly assigned to a bit more
than 100 respondents per block. Two scenarios per block were
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Figure 1 Spread of gains across the utility plain.
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randomly assigned to one of the 10 blocks, and three were
purposefully selected into blocks. These scenarios were assigned
to blocks in order to ensure that in each block, the respondents
encountered health gains situated on the low, middle, and high
end of the utility scale (according to Dutch EQ-5D tariffs). Given
the design, the changes in health between two health states
(according to Dutch EQ-5D tariffs) ranged from 0.004 to 0.738
QALY, with a mean of 0.32 and a median of 0.34 QALY. Several
scenarios were designed such that one health state was unam-
biguously better than the other.
QALY gains were also calculated from sample-speciﬁc VAS
scores [28] obtained from the valuations in the questionnaire
(i.e., “raw” scores); mean (and median) scores of perfect health
and death were used for rescaling, based on the formula:
X
X X
X X
rescaled
raw mean of death
mean of perfect health mean
=
−
−  of death
Combining the highest (€2500) and the lowest values (€10) of
the PS with the minimum (0.004) and the maximum (0.738)
QALY gains deﬁned by the design produces an implicit
maximum WTP of €7,500,000 (2500/0.004 * 12) and an implicit
minimum WTP of €163 (10/0.738 * 12), with an implicit average
WTP for a QALY of €17,862 (476.31/0.32 * 12) (see Appendix 2
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i8_Bobinac.asp). The ratio is multiplied by 12 because we
ask about the monthly installment and a yearly health gain.
Analysis
WTP per QALY was calculated as the ratio of the WTP for
avoiding the move from the better to the worse health state to the
QALY difference between the two health states. This ratio was
calculated for two utility elicitation techniques (i.e., using EQ-5D
tariffs and EQ-VAS scores), two WTP elicitation techniques (i.e.,
PS and “bounded” OE formats), and for each of the ﬁve sce-
narios (i.e., taking the means of ratios of each individual sce-
nario). The approach of taking the mean of ratios accounts for
the individual variation in the marginal utility of income, and
overall heterogeneity in preferences, because individuals’ WTP
for a QALY is directly imputed into the calculation of the mean.
The most relevant WTP per QALY estimate was calculated based
on valuations from the bounded direct “OE” follow-up question.
The heterogeneity in WTP per QALY ratios was primarily
examined from the perspective of: 1) the level of household
income, using the income categories presented in Table 1; and 2)
the level of certainty in the WTP answers, by comparing the
sample average WTP per QALY to the WTP per QALY of the
respondents indicating the highest levels of certainty (pretty sure
and totally sure).
The theoretical validity of our results was examined with a
log-linear clustered multivariate regression analysis with raw
WTP estimates and WTP per QALY estimates as dependent
variables. Both variables were expected to increase with the level
of household income and to decrease with the number of people
depending on this income, while raw WTP was also expected to
increase with the size of the projected health gain. Within the
multivariate regression context, we also explored if the health
status of respondents and/or existence of chronic illnesses would
in any way affect the WTP per QALY estimate.
Separate regressions were conducted for each of the utility
and WTP elicitation techniques. Variables and their associations
were compared using parametric and nonparametric tests. The
results of the PS were tested for order bias by comparing the
WTP estimates between samples that solved the same blocks of
scenarios in different orders. The speciﬁcation of the PS, and the
mid-point and end-point bias, were investigated by examining
response patterns on the PS, both in the pilot and the main study.
The relationship between EQ-VAS and EQ5D tariffs was checked
for consistency. All analysis was conducted using STATA for
Windows version 10.
Results
One thousand ninety-one respondents, representative of the
Dutch population according to age (18–65 years), sex, and edu-
cation, participated in the survey. The description of the sample
is given in Table 1. The respondents were predominately married,
employed, and in very good health (EQ-5D 0.84; EQ-VAS 78.5)
(39% of the sample reported suffering from a chronic condition,
and although the severity of the condition was not speciﬁed,
given the average score on the EQ-VAS and EQ-5D tariff, we can
assume that the respondents predominately suffered from very
mild or mild chronic conditions.). The sample average net house-
hold income of €2564 a month, with an average of 2.44 house-
hold members depending on that income, adequately represents
the Dutch national ﬁgures for 2008 [42].
WTP for Nonhealth Items
The respondents gave plausible estimates of WTP for a car (mean
€10,900, median €7000), a pair of shoes (mean €109, median
€80), and housing (mean €201,600, median €200,000) of their
choice. From this, we inferred that the respondents understood
the exercise, although the focal point of the exercise—
health—may be more difﬁcult to value, as normal (direct) market
prices are absent.
Utilities
The correlation between utility scores obtained from the EQ-VAS
scores and the Dutch EQ-5D tariffs was low (r = 0.24). The
Table 1 Summary statistics (n = 1091)
Variable Mean SD Min Max
Age 42.1 12.1 18 65
Sex (% male) 0.47 0.50
Marital status:
Married (% yes) 0.61 0.49
Divorced (% yes) 0.10 0.31
Single (% yes) 0.24 0.43
Widow (% yes) 0.03 0.16
Unknown (% yes) 0.02 0.14
Children (% yes) 0.56 0.50
Number of children (n = 3070) 2.23 10.1 1 10
Income groups:
Group 1 (% <€1000) 0.13 0.33
Group 2 (% >€999 and
<€2000)
0.34 0.48
Group 3 (% >€1999 and
<€3500)
0.40 0.49
Group 4 (% >€3499) 0.12 0.33
Number of people living on
household income
2.44 10.4 1 20
University education (% yes) 0.36 0.48
Employment status
Employed (% yes) 0.62 0.48
Unemployed (% yes) 0.17 0.38
Student (% yes) 0.06 0.25
Housewife/husband or retired
(% yes)
0.14 0.35
Health status
EQ-5D (Dutch tariff) 0.84 0.22 -0.26 1
EQ-VAS 78.5 170.1 0.00 100
Suffering a chronic illness
(% yes)
0.39 0.94
Completion time of the
questionnaire
18.8 60.13 9 61
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average health gain was 0.32 (SD 0.2; median 0.34) based on
EQ-5D tariffs and 0.33 (SD 0.29; median 0.25) based on the
EQ-VAS. Although the average scores do not differ considerably,
there is a statistically signiﬁcant difference between them
(P = 0.02). The tests of consistency between EQ-VAS and the
Dutch EQ-5D tariffs conducted on the level of particular health
states showed that the two valuation techniques especially pro-
vided similar valuations for health states situated in the middle
range of the utility scale. It was tested and conﬁrmed that the
better health states received, on average, higher valuations on the
EQ-VAS. The respondents reversed the ranking (i.e., valuing
the obviously worse health state higher on the EQ-VAS) on
average in only 7% of scenarios.
Patterns inWTP Answers
Data inspection did not disclose any unusual patterns. Less than
1.5% of the respondents chose the highest level offered on the PS
(i.e., €2500). Sixty-two respondents indicated, in one or more
scenarios, that they would not pay more than €0 for a health gain
(only 23 respondents indicated €0 in all ﬁve scenarios). No
consistent relationship was found between the size of the health
gain, household income, and zero WTP. The interpretations of
zero WTP were uniformly distributed among the offered expla-
nations, and protest answers were observed in only 1.4% of all
scenarios. We therefore proceeded with the analysis without spe-
ciﬁcally considering (or excluding) these responses.
The distribution of the certainty in the provided answers
revealed that the majority of respondents (56%) was either pretty
or totally sure that they would actually pay the stated amount for
the speciﬁed health gain; 33% indicated uncertainty, 8% was not
very sure they would pay, and 3% indicated they were unsure
they would pay. The majority of the respondents would give up
charitable donations or savings if they needed to pay for the
medicine out-of-pocket.
Test results did not indicate that the mid-point or range bias
played a noteworthy role in our study. The results show a highly
left-skewed distribution of values chosen from the PS. Although
the results did not concentrate at one particular amount on the
scale, the majority of values chosen on the scale fell between €50
and €200. Finally, the tests showed that WTP per QALY elicited
when the scenario offering the largest gain was presented ﬁrst in
a block did not differ from WTP per QALY estimates elicited
when the scenario offering the smallest gain was presented ﬁrst,
thus refuting the order bias.
MaximumWTP per QALY
The estimates of WTP per QALY varied considerably with the
method of calculation. Table 2 provides the breakdown of WTP
per QALY values according to: 1) the source of health state
valuations; 2) the two steps in the WTP elicitation (i.e., lower
bound of the PS, that is, the amount people deﬁnitely would pay,
and the OE follow up); and 3) the level of certainty. In the
bounded OE follow-up question, the respondents elicited a
maximum WTP per QALY of €24,500. Estimates were system-
atically lower when QALY gains were calculated using the
EQ-VAS scores (i.e., €12,900 and €17,000, rescaled on mean or
the median). The estimates were higher among the respondents,
indicating a high level of certainty in their answers, although the
differences were not considerable. All estimates presented in
Table 2 were statistically different from each other (P = 0.00).
Finally, as an additional test, a zero WTP was assigned to
responses that were “unsure” about the elicited WTP. This did
not result in a signiﬁcant change in the mean WTP (P = 0.07).
Subgroup Analyses
WTP per QALY varied considerably with household income in
the expected direction, and reached €55,900 in the highest
income group (Table 3). As noted before, the respondents indi-
cating a higher level of certainty in their answers produced some-
what higher WTP per QALY estimates; those in the highest
income group and with the higher certainty level elicited a mean
individual WTP per QALY of €75,400 (using Dutch EQ-5D
tariffs; see (3) in Table 3). VAS scores yielded considerably lower
estimates (up to €35,300 for those in the highest income and
certainty group; see (2) in Table 3). Differences in WTP per
QALY were, however, only statistically signiﬁcant between
income group 4 and other groups (P = 0.00).
WhatWould You Not Pay?
On the PS, the respondents indicated that the minimum amount
they were certainly not willing to pay for a QALY was €43,160
(see (3) in Table 4). Again, estimates were higher for respondents
who were more certain in their answer (up to €48,600), for
higher income groups (up to €86,100), and these characteristics
combined (up to €114,900). Using VAS scores in the calculation
of the amount the respondents were not willing to pay for a
particular gain yields the estimate of up to €54,000 (see (2) in
Table 4).
Theoretical Validity
Table 5 presents the results of multivariate logarithmic regres-
sions with raw WTP values and WTP per QALY estimates as
dependent variables. t Tests showed that all independent vari-
ables were statistically signiﬁcant (at 1 or 5% level), and F test
showed that the regression equations were statistically signiﬁcant
at any regular level. Results for health gains computed using
median-rescaled VAS scores were omitted because they are highly
comparable to the mean-rescaled ones.
The results are in line with a priori expectations; the WTP
were positively associated with the size of the health gain and
with household income, the latter effect being the strongest (beta
coefﬁcients, not presented here). Regression analysis of WTP per
QALY estimates showed a positive association with the size of
Table 2 Willingness to pay (WTP) per quality-adjusted life-year (€, rounded to hundreds)
All respondents: average
[n = 1,091, f = 5,253]; (SD)
Certainty level: pretty sure or totally
sure [n = 761, f = 2,984]; (SD)
1. WTP: EQ-VAS, mean rescaled WTP: PS 9,600 (35,800) 10,400 (32,900)
WTP: OE 12,900 (48,100) 13,100 (37,900)
2. WTP: EQ-VAS, median rescaled WTP: PS 12,600 (47,100) 13,700 (43,200)
WTP: OE 17,000 (63,200) 17,300 (49,800)
3. WTP: Dutch EQ-5D tariffs WTP: PS 17,900 (172,100) 21,200 (181,600)
WTP: OE 24,500 (213,600) 26,800 (204,300)
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the household income as well, and a negative association with the
number of household members supported by the household
income.
In both sets of regressions, dependent variables increased
with the level of education, as also found by Zethraeus [43], and
decreased with age [20,44]. Current health status, being chroni-
cally ill and subjective life expectancy, was not associated with
raw WTP or WTP per QALY (regressions not presented here).
The R2 were low, similar to related work [21].
Discussion
Recently, more empirical research to determine the monetary
value of a QALY has been called for and initiated (see e.g.,
[19,20,44,45]). In this context, we estimated the ﬁrst monetary
value of a QALY in The Netherlands, using a comprehensive
valuation exercise from the individual perspective. The results
show that the maximum WTP for a QALY, derived through
aggregating and averaging individual responses, is €24,500.
As we have shown, however, the estimates of the WTP per
QALY can vary substantially, depending on the speciﬁc sub-
groups and methods of calculation. In terms of the latter, using
the VAS valuations of the health changes rather than the TTO
tariffs, resulted in an average estimate of €12,900. Such a dis-
crepancy between TTO-based values and VAS-based values of
the maximum WTP per QALY has been noted before [21,46].
Indeed, the two techniques are known to yield different esti-
mates, but the debate regarding their acceptability or accuracy is
well beyond the scope of this article (see e.g., [47] for a further
discussion on VAS). For the current purpose, we consider the
EuroQoL-5D tariffs to be more relevant because they are most
commonly used and derived in a standardized way. In terms of
the former, valuations of subgroups stratiﬁed by income level and
level of certainty, proved to differ substantially. The richest, most
certain subgroup elicited a considerably higher WTP per QALY
(i.e., €75,400; their upper-bound estimate using the PS is
€114,900). It seems important to stress these variations and to be
careful with terms as “the value” of a QALY. Similarly, the SDs
around our WTP estimates were considerable, indicating a large
variation in preferences. The level of variation is lowest for the
lower-bound estimates of WTP (i.e., highest amount people cer-
tainly would pay, as indicated on the PS) and increases with the
size of WTP. Moreover, it is also important to note that the
individual valuations can be combined in different ways to come
to a value of a QALY. Aggregating in a different way than the one
chosen here (i.e., taking the mean of ratios) is likely to result in
different estimates of WTP per QALY. Such methodological
aspects of deriving monetary values from the “raw material”
deserve more attention, especially because there appears to be no
guidance or consensus on this topic.
The results presented here align with the relevant range of the
cost-effectiveness threshold of £20,000 to £30,000 (or €23,300
to €35,000) used by NICE in recent years [2] and the most
commonly cited threshold of €20,000 in The Netherlands (e.g.,
[48]). Similar results were recently derived from the existing
value of preventing a statistical fatality in the UK context, with
estimates ranging between £23,199 (€26,877) and £40,029
(€46,375) per QALY [44]. Gyrd-Hansen ([20]), using a DCE
approach and TTO utilities, estimated a WTP per QALY of
€12,000 in the general population of Denmark for relatively
small-sized health gains. King et al. [21] reported on WTP per
QALY ratios obtained in three distinct patient populations. Using
VAS, Standard Gamble, and TTO to elicit utilities, they found a
maximum WTP per QALY ranging from $12,500 (€9500) to
$32,000 (€24,500). Recently, Shiroiwa et al. [4] estimated the
WTP for an additional year of survival in full health, and found
that the mean WTP per QALY ranged from £23,000 (€26,600) in
the UK, AU$64,000 (Australia; €36,600) to US$62,000 (US;
€44,000). Seemingly, the available empirical estimates range
roughly between €10,000 and €45,000—aligning with the lower-
and upper-bound estimates for the full sample obtained in the
current study.
We note that our results may have been inﬂuenced by several
methodological issues that deserve attention. First is the range of
values offered on the PS [49,50]. We carefully pretested the range
of the scale in a pilot study and, to minimize the mid-point bias,
employed a two-question procedure in using the PS. The majority
of values chosen on the scale fell between €50 and €200. The
end-point bias could be rejected, because only a few respondents
(in less than 1.5% of scenarios) opted for the highest amount
offered on the scale (i.e., €2500). Nevertheless, some concerns
remain with the range of the scale because the results could not
Table 5 Multivariate clustered regression analysis
EQ-VAS scores (mean rescaled) Dutch EQ-5D tariffs
WTP: PS WTP: OE WTP: PS WTP: OE
Coef SE P > |t| Coef SE P > |t| Coef SE P > |t| Coef SE P > |t|
DV: log(raw WTP)
Heath gain: log(EQ-VAS) 0.05 0.02 0.06 0.06 0.03 0.02
Health gain: EQ-5D tariff 0.13 0.05 0.02 0.13 0.06 0.04
Log(income) 0.74 0.07 0.00 0.81 0.09 0.00 0.73 0.07 0.00 0.79 0.09 0.00
Log(age) -0.21 0.1 0.03 -0.33 0.11 0.00 -0.21 0.09 0.02 -0.33 0.11 0.00
Higher education 0.25 0.07 0.00 0.23 0.07 0.00 0.25 0.06 0.00 0.22 0.07 0.00
Number of people living on household income -0.07 0.02 0.00 -0.09 0.03 0.00 -0.07 0.02 0.00 -0.08 0.03 0.00
Intercept -0.55 0.57 0.34 -0.42 0.67 0.53 -0.58 0.56 0.29 -0.37 0.67 0.58
N 4982 4841 5029 5184
R2 0.11 0.12 0.12 0.18
DV: log(WTP/QALY)
Log(income) 0.71 0.08 0.00 0.78 0.10 0.00 0.72 0.07 0.00 0.79 0.10 0.00
Log(age) -0.24 0.11 0.00 -0.35 0.12 0.00 -0.28 0.10 0.01 -0.40 0.11 0.00
Higher education 0.31 0.08 0.00 0.29 0.08 0.00 0.20 0.07 0.00 0.18 0.08 0.02
Number of people living on household income -0.07 0.03 0.01 -0.08 0.03 0.01 -0.07 0.03 0.01 -0.08 0.03 0.01
Intercept 3,6 0.65 0.00 3,7 0.73 0.00 3,7 0.59 0.00 3,8 0.70 0.00
N 4841 4982 5029 5184
R2 0.07 0.08 0.06 0.06
DV, dependant variable.
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be compared to results from a scale of a different range. The
range may thus be limiting both the WTP estimates and the
difference between WTP per QALY values stemming from the PS
and the “bounded” OE question. Nevertheless, the use of a
two-step procedure in deriving WTP estimates proved feasible
and helpful, yet it must be noted that using other elicitation
techniques may result in different estimates of WTP. This seems
an important area for further research.
Furthermore, it could be argued that the respondents’ ability
to pay constrained the monetary value of a QALY, especially in
light of nonmarginal health gains employed. Nevertheless, the
data show that this too could only be a minor problem. The
average maximum WTP for an average gain of 0.33 (VAS) or
0.32 (EQ-5D tariffs) was €174 a month, while the average
household income was €2564. (The ﬁgure €24,500 was calcu-
lated based on the formula WTP per QALY * 12 for each indi-
vidual scenario. Taking the average WTP of €174 and
multiplying it by 12/0.32 would lead to a more conservative
estimate that does not take the distribution of individual valu-
ations into account). This suggests that the respondents were
not bidding to the point of a catastrophic payment (i.e., on
average spending 6.79% of monthly income) or that the ability
to pay limited the expressed WTP. Still, employing marginal
gains would decrease such concerns even further, which could
result in higher estimates of WTP. In that sense, our estimates
might be seen as lower bounds of the WTP per QALY [1].
Nevertheless, using marginal increments could raise questions
regarding the extrapolation of obtained WTP estimates to sce-
narios in which nonmarginal health improvements are relevant
[20]. Second, the respondents only valued potential health
improvements and not potential mortality reduction. While
many health-care interventions are indeed aimed at improving
quality of life rather than reducing mortality, which emphasizes
the relevance of the here presented ﬁgures, obtaining estimates
in the context of mortality reduction remains important. It is
likely that such estimates would be higher than the ones pre-
sented here [16,44]. Such scenarios would, unlike the ones used
here, require valuations under risk rather than under certainty.
While this has advantages such as marginality when using small
risks, it also entails disturbing elements like risk weighting,
which would need to be accounted for in analyzing the results.
Third, the choice of the payment vehicle and frequency could be
another important contextual determinant of the size of WTP
per QALY estimate. In this study, WTP was elicited in relation
to actual use of the intervention (as opposed to an “insurance”
context) and payments phrased as monthly outlays (as opposed
to, e.g., a lump sum). Although individuals in The Netherlands
are somewhat acquainted with paying out-of-pocket for health
care (according to OECD [51], 8% of all health care is ﬁnanced
out of pocket) and increasingly so since the introduction of a
mandatory deductible [52], it remains unclear to what extent
the type of payment seemed realistic to respondents. A similar
issue has been reported by [53], and it limits the applicability of
the results. Phrasing the payments in terms of a lump sum might
have produced more conservative estimates because it does not
offer the opportunity of spreading the burden over time [54],
but could induce problems of ability to pay and budget con-
straints. Fourth, the relative position of the respondent’s own
health and the health states valued could have affected the WTP
valuations because some health states could have been consid-
ered as a relative gain or a loss. Although most respondents’
own health was evaluated higher than the health states pre-
sented in the questionnaire, in the analysis, we took the usual
assumption that, given the instructions, own health is, in fact,
irrelevant for the valuation. Our data did not allow a ﬁrm test
of whether this assumption actually holds. Similarly, the style or
framing of the WTP question (i.e., valuing gains in health as
opposed to valuing avoiding a loss in health) could have had an
effect on WTP. Although these issues, and the scale of their
impact, are beyond the scope of this study, they remain inter-
esting empirical and theoretical questions. Finally, an important
limitation of this study (and other preference elicitation studies)
is the hypothetical nature of the exercise. Similar to other
studies, the respondents might have found it difﬁcult to imagine
being in a health state other than what they have experienced.
The same holds for other elements of our questionnaire (i.e., the
concept of painless cure or the duration of health loss of pre-
cisely 12 months). Regardless of the effort put into increasing
realism and reducing the hypothetical bias (i.e., through ex ante
and ex post-mitigation), it is uncertain whether the elicited WTP
corresponds to the real (i.e., revealed) WTP. Some have indi-
cated that the subgroup of most certain respondents would
produce an estimate of WTP that is fairly close to “real” WTP
[55]. In this study, this implies that a slightly higher estimate of
WTP per QALY—€26.800 instead of €24.500—would be rel-
evant (Table 2). Given that the two estimates are not consider-
ably different, that only one is informed by all respondents and
that it has been recommended [35] to use conservative estimates
in contingent valuation studies, we have focused here on the
estimate of €24.500. Encouragingly, as seen above, our results
compare well to the relevant range of the most often cited cost-
effectiveness threshold.
Some issues need to be addressed concerning the use of the
ﬁgures presented here in the context of health policy. First, the
ﬁgures are lower than some thresholds that have been mentioned
elsewhere, such as the $50,000 or $100,000 threshold in the US
context or, for instance, the upper limit of €80,000 proposed in
The Netherlands by an important advisory body RVZ [56].
Moreover, they are lower than what we infer from a part of the
value-of-life literature (e.g., [57]). Our estimates are also lower
than the estimates of WTP for a life-year saved [58]. Such large
variations, undoubtedly fuelled by underlying methodological
differences, exist and need to be explicitly addressed before rec-
ommending the use of particular thresholds in health policy. One
of the key normative and methodological issues is the perspective
from which the appropriate height of the cost-effectiveness
threshold needs to be determined [13,59]. This appears to be an
essential element in future theoretical and empirical work. For
instance, the €80,000 threshold in The Netherlands was not
proposed as a ﬁxed threshold, but as the maximum of a range.
Importantly, this range does not increase with individual valua-
tions (such as income in our study), yet is increasing with more
socially driven considerations, namely disease severity, which can
be seen as an equity consideration [60]. NICE, perhaps some-
what similar, asks that a technology with the ICER of over
£20,000 per QALY needs to make explicit references to “the
particular features of the condition and population receiving the
technology” as to increase its chances of being accepted [61].
Recently, NICE even indicated that certain interventions (i.e.,
lifesaving cancer drugs) may be approved in spite of less favor-
able cost-effectiveness [62,63].
Equity considerations thus appear to play a role in societal
decisions. Indeed, when looking at the literature regarding
“equity weights,” this becomes even clearer (e.g., [17,64]).
People attach weights to health gains according to the “the
particular features of the condition and population receiving the
technology,” it seems. Importantly, though, such preferences are
most likely not reﬂected in individual valuations of own health
gains. This raises the issue of usefulness of individual valuations
in the current context.
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If we are, however, to consider individual valuations of health
gains as relevant for societal decisions on the allocation of health-
care resources, the question of how to use these individual valu-
ations is important. For example, in this study, we ﬁnd a great
variation in WTP across income groups. The average individual
threshold of €24,500 is therefore only the “right” valuation for a
small group of individuals. From a traditional normative welfare
economic viewpoint, it is easy to argue that simply taking the
average can result in systematically “wrong” decisions. Indeed,
applying such a cost-effectiveness threshold “unduly” restricts
the provision of expensive interventions to the rich part of the
population (as true beneﬁts are higher than projected), while it
“unduly” grants them to poorer groups (because the true beneﬁts
are lower than projected). A similar argument extends to the use
of the mean monetary value of premature fatality (i.e., value of a
statistical life) as a threshold in economic evaluations done by the
UK Department of Transport.
This practice resembles an implicit weighting procedure (of
valuations), from an individual perspective. While we may wish
to do so for many reasons, welfarist or extra-welfarist [65], the
justiﬁcation of using the average (as opposed to the median or the
maximum) needs to be clear, and still is not (e.g., [66]).
If, on the contrary, we expect that individual valuations of
own health gains may not be directly relevant for the societal
decisions we are faced with, it may be worthwhile attempting to
directly elicit something like the “societal WTP for a QALY.”
Such an ex-ante value should be the focus of future research. In
our view, it should include aspects like option value and solidar-
ity, and would be allowed to vary with characteristics of the
beneﬁciaries of health-care interventions such as disease severity
and age (instead of income). Indeed, in the context of the collec-
tive decisions in the health-care sector involving (risk and
income) solidarity and other-regarding preferences, one may con-
sider valuations directly derived from a societal perspective to be
more relevant for the question at hand. This then allows a direct
link between equity weights and the value of QALY gains, as well
as a transparent public discourse (if not consensus) on what the
desirable weights should be. It does require, however, that such
valuation studies are appropriately designed, also in order to be
able to interpret the results straightforwardly.
It seems, therefore, that the quest of ﬁnding appropriate
monetary values is just beginning. While this study hopes to have
contributed in this quest, it is clear that important normative and
methodological issues need to be addressed before the results can
be used in a policy context.
Source of ﬁnancial support: This study is part of a larger project investi-
gating the broader societal beneﬁts of health care, which was ﬁnancially
supported by Astra-Zeneca, GlaxoSmithKline, Janssen-Cilag, Merck, and
Pﬁzer BV. The researchers were free in study design; collection, analysis,
and interpretation of data, as well as in writing and submitting the article
for publication. The views expressed in this article are those of the authors.
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